Can adipokine visfatin be a novel marker of pregnancy‐related disorders in women with obesity?. (27th March 2020)

• Record Type: Journal Article
• Authors: Wnuk, Anna; Stangret, Aleksandra; Wątroba, Mateusz; Płatek, Anna E.; Skoda, Marta; Cendrowski, Krzysztof; Sawicki, Włodzimierz; Szukiewicz, Dariusz
• Is Part Of: Obesity reviews. Volume 21:Number 7(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-03-27
• Subjects: obesity -- pregnancy -- visfatin; Obesity -- Periodicals; 616.398005
• DOI: 10.1111/obr.13022
• Languages: English
• ISSNs: 1467-7881

Abstract

Summary: Overweight and obesity have become a dangerous disease requiring multiple interventions, treatment and preventions. In women of reproductive age, obesity is one of the most common medical conditions. Among others, obese state is characterized by low‐grade systemic inflammation and enhanced oxidative stress. Increased maternal body mass index might amplify inflammation and reactive oxygen species production, which is associated with unfavourable clinical outcomes that affect both mother and child. Intrauterine growth retardation, preeclampsia, or gestational diabetes mellitus are examples of the hampered maternal and foetoplacental unit interactions. Visfatin is the obesity‐related adipokine produced mainly by the visceral adipose tissue. Visfatin affects glucose homeostasis, as well as the regulation of genes related to oxidative stress and inflammatory response. Here, we review visfatin interactions in pregnancy‐related disorders linked to obesity. We highlight the possible predictive and prognostic value of visfatin in diagnostic strategies on gravidas with obesity.